Idorsia
Idorsia Ltd is a Swiss biopharmaceutical company focused on the discovery, development, and commercialization of innovative small-molecule drugs targeting serious medical conditions. The company utilizes its specialized drug discovery platform and pharmacological expertise to develop therapeutic candidates across fields such as neurology, cardiology, and immunology, prominently featuring commercialized products like Quviviq (daridorexant) for insomnia. Its core operations encompass preclinical research, clinical trial advancement, regulatory compliance, and commercial pharmaceutical distribution. Revenue is derived primarily from the commercial sales of its approved drugs in international pharmaceutical markets, alongside strategic licensing agreements. Idorsia holds a specialized position in biopharmaceutical drug discovery and clinical development. The company is headquartered in Allschwil, Switzerland, and its shares trade on the SIX Swiss Exchange.
3 of the funds FundTelligence covers report a position in Idorsia.
- Legal name
- Idorsia Ltd
- Sector
- Health Care
- Country
- Switzerland
- Funds holding it
- 3
Funds holding Idorsia
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.09 % (full portfolio disclosed, October 2026)
- Storebrand Global Multifactor — Storebrand · 0.05 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)